Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
WHO prequalifies OraQuick; first self-test for hepatitis C virus
OraQuick HCV Rapid Antibody Test is specifically designed for use by lay users and provides individuals with a single kit…
The growing threat of antibiotic resistance
Bhupendrakumar Chudasama, Associate Dean, Research and Development Cell at Thapar Institute of Engineering and Technology, Patiala…
Indegene collaborates with Microsoft to promote use of GenAI in global life sciences companies
Indegene and Microsoft have aimed to develop resources in highly specialised and skilled medical and technology tools to…
US FDA declines to approve Novo Nordisk’s weekly insulin
The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1…
Zydus gains final FDA nod for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and…
Prioritised investments from pharma companies shaping competitive pipeline landscape of…
In recent years, bronchiectasis has garnered a significant amount of attention, with pharmaceutical companies prioritising their…
33rd CRSI-National Symposium in Chemistry concluded in Hyderabad
Hosted by Dr Reddy's Laboratories, the symposium showcased the latest research and fostered networking opportunities, with the aim…
The next frontier: Global leadership in biopharma
Cutting-edge research, future-ready talent, next-gen infrastructure, judicious investments and strategic collaborations are…
Emcure makes a premium of 31.5 per cent over IPO price
Emcure's IPO ran from July 3 to July 5 and is a book-built issue valued at Rs 1,952.03 crores